Shares: 33.9 mill; price $1.63. Options: 4.2 mill to convert to shares by payment of $2.50 on 31 May 2005; code PGLO. Another 0.92 mill unlisted options. Cash: $16 mill. on Nov. 11, 2003.
PGL also manufactures drugs for other companies.
1. DRUG PI-88 Oct 3, 2000: Commences New Human Trials: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=136866
Nov. 23, 2000: US Patent granted for Anti-cancer/Anti-thrombotic Drug: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=137957
Febr.2, 2001:Clears first clinical trial hurdle with concl of PI Phase 1b--Preparing for Phase II: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=138995
March 26, 2001: Launch of inflammatory disease research program: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=139826
April 11, 2001: Alliance Partner to Conduct Indep. Phase 1b Clinical Trial: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=140084
June 6: US Patent granted for gene encoding Heparanase enzyme: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=140838
Aug 2, 2001: 1st US Clinical trial with anti-cancer drug PI-88 commences (Advanced Melanoma): http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=141718
Aug. 13, 2001: ComplementaryUS Patient Granted for Progen`s Lead Drug PI-88: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=141893
Nov. 20, 2001: PI-88 a potential leukaemia drug: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=143774
Jan. 22, 2002: Australia, start of Phase II clinical trial (Mult. Myeloma) http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=144843
June 5, 2002: Combination trial ( PI-88 + Taxotere), Phase I, to start in the US in July (Melanoma): http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=146912
July 9, 2002: PGL has reached a significant milestone in its program to develop novel drugs to inhibit the enzyme heparanase. http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=147368
Nov. 25, 2002: Encouraging Human Trial Data from Progen`s PI-88 (Prel. data from Phase I/II , Melanoma and Renal-cell Carcinoma) presented in the US: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=149993
May 7, 2003: Additional Results Support Cancer Trials Strategy-Three clinical trials investigating the therapeutic effect of PI-88 on solid tumours including melanoma, lung and liver cancers are underway: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=152738
IMPORTANT: June 4, 2003: Recent International Clinical Results Validate PGL's Strategy: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=153158
July 8, 2003: Achieves efficacy endpoint in Phase II Multiple Myeloma Trial (Australia): http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=153679
Sept. 30, 2003: Progen's PI-88 Presented at US Antiangiogenesis Conference:
“Progen’s lead drug candidate PI-88 also targets VEGF along with other cancer-related growth factors such as b-FGF as well as heparanase, a degrading enzyme associated with angiogenesis and metastasis.” http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=155338
Jan. 21, 2004: PI-88 Melanoma Phase II trial commenced-Joint Australia and US. " Rob Don, Progen’s VP of R&D commented “PI-88 has been well tolerated by patients in the Phase I trial.
We have also seen positive signs that PI-88 has retarded tumor growth in over 40% of the melanoma patients for periods lasting up to 30 months.
This Phase II clinical trial in advanced melanoma patients is the first of three new PI-88 Phase II trials that will be initiated in the near future":
"Melanoma is the number one cause of cancer death in women aged 25 to 30. For more information on melanoma please visit: http://www.nci.nih.gov/cancer_information/cancer_type/melanoma
2. DRUG PI-166: Sept 18, 2002: PI-166 added to Development Pipeline: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=148587
Jan. 13, 2003: Commences Human Liver Cancer Phase 1b Trial with PI-166- St. George, Sydney. http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=150786
3. OTHER: Dec 17, 2001: US Funding for Progen (Malaria studies): http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=144238
June 7, 2002: Second Provisional Specification: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=146958
Aug. 19, 2002: Media Release: Manufacturing Alliance with CSIRO: http://stocknessmonster.com/news-item?S=PGL&E=ASX&N=148001
Gerry Stolwyk Readers, please do your own research and you decide if and when to buy, hold or sell any stocks.
PGL Price at posting:
0.0¢ Sentiment: None Disclosure: Held
(20min delay)